85504-84-3

Basic information

• Product Name: 3-acetyl-3,12-dihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxyhexopyranoside
• Synonyms: (9S)-9-acetyl-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9-dihydroxy-, (7S-cis)-
• CAS NO: 85504-84-3
• Molecular Formula: C₂₆H₂₇NO₈
• Molecular Weight: 481.4945
• Mol File: 85504-84-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 706.4°C at 760 mmHg
• Flash Point: 381°C
• Density: 1.49g/cm³
• Vapor Pressure: 6.04E-21mmHg at 25°C
• Refractive Index: 1.685
• CAS DataBase Reference: 3-acetyl-3,12-dihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxyhexopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: 3-acetyl-3,12-dihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxyhexopyranoside(85504-84-3)
• EPA Substance Registry System: 3-acetyl-3,12-dihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxyhexopyranoside(85504-84-3)

Safety Data

• Hazardous Substances Data: 85504-84-3(Hazardous Substances Data)

Upstream product

• 60660-74-4 (+)-N-Trifluoroacetyl-4-demethoxydaunorubicin 
• 57852-57-0 idarubicin hydrochloride 

Relevant articles and documents

Stable and safe idarubicin pharmaceutical composition and preparation method thereof

The invention discloses a stable and safe idarubicin pharmaceutical composition and a preparation method thereof. The pharmaceutical composition contains idarubicin or a pharmaceutically acceptable salt thereof and a compound of formula A or a pharmaceutically acceptable salt thereof in an amount of no more than 0.3%. According to the method, an impurity A in idarubicin is separated and confirmed.Prior to this, there is no report that the impurity A is present in the idarubicin. The impurity A is fully researched, it is found that the existence of the impurity A affects the physical and chemical stability of idarubicin and increases cardiac toxicity of idarubicin. The pharmaceutical composition enables idarubicin to maintain good stability. The invention further provides a method for preparing the impurity A. The high-purity impurity A can be acquired to serve as a reference sample or a standard sample for controlling the content of the impurity A in idarubicin and preparations thereof.